文献速递妇科

促性腺激素释放激素拮抗剂(linzagolix):子宫腺肌症的新疗法

Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
PubMed 文献 · Fertil Steril · 2020-06-02

本病例报告描述一名1981年出生、经MRI确诊为弥漫性子宫腺肌症的患者,因月经过多、盆腔痛和痛经就诊。患者先接受醋酸乌利司他每日5 mg治疗3个月,因MRI示病灶加重而停药;一年后改用linzagolix每日200 mg口服3个月,继以每日100 mg再用3个月,期间闭经、症状显著改善,子宫体积由875 cm³降至290 cm³,腺肌症病灶显著消退。

要点

  • 醋酸乌利司他每日5 mg治疗3个月期间症状加重、MRI示腺肌症病灶加重。
  • linzagolix每日200 mg治疗12周期间患者闭经,症状非常显著改善。
  • MRI示子宫体积由875 cm³降至290 cm³,腺肌症病灶显著消退。

核心结论

  • 据作者所知,这是首次报道linzagolix用于一名对选择性孕激素受体调节剂醋酸乌利司他先前无应答的重度子宫腺肌症患者,显著缩小病灶并改善生活质量。

研究设计与样本

  • 病例报告,设置于私人诊所与不孕研究单位,患者1例,1981年出生,经MRI确诊为弥漫播散性子宫腺肌症。

主要发现

  • 醋酸乌利司他每日5 mg治疗1个疗程3个月期间,盆腔痛、痛经、占位症状加重,MRI示腺肌症病灶加重。
  • linzagolix每日200 mg口服12周期间患者维持闭经,症状非常显著改善。
  • MRI示子宫体积由875 cm³降至290 cm³,腺肌症病灶显著消退。
  • linzagolix每日100 mg治疗第13至24周期间,患者报告症状持续缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of a selective progesterone receptor modulator, ulipristal acetate, and a gonadotropin-releasing hormone antagonist, linzagolix, in a case of severe uterine adenomyosis. DESIGN: Case report. SETTING: Private clinic and infertility research unit. PATIENT: One patient born in 1981 who presented because of heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis confirmed by magnetic resonance imaging (MRI). INTERVENTION: The patient received a first treatment of 5 mg UPA daily for one course of 3 months. This therapy was discontinued because MRI revealed a worsened aspect. One year later, a once-daily dose of 200 mg linzagolix administered orally was initiated for 3 months, followed by another 3-month course of 100 mg once daily. MAIN OUTCOME MEASURES: Clinical symptoms and MRI aspect. RESULTS: During treatment with UPA, the symptoms (pelvic pain, dysmenorrhea, bulk symptoms) worsened and MRI revealed aggravation of the adenomyotic lesions. During the 12-week course of once-daily 200 mg linzagolix, the patient remained in amenorrhea and noted a very significant improvement in symptoms. On MRI, the uterine volume had fallen from 875 cm3 to 290 cm3, and the adenomyotic lesions had significantly regressed. During the 100-mg linzagolix course (weeks 13-24), the patient reported continued alleviation of her symptoms. CONCLUSION: To our knowledge, this is the first reported use of linzagolix, a new oral gonadotropin-releasing hormone antagonist that significantly reduced lesion size and improved quality of life in a patient with severe adenomyosis, who was previously nonresponsive to treatment with a selective progesterone receptor modulator, ulipristal acetate.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020. PMID: 32507315. doi:10.1016/j.fertnstert.2020.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。